Meridian Continues to Support Trials at Sites Nationwide, Will Remain Operational Amid COVID-19 Pandemic

Meridian Clinical Research, a leading investigative research network, will remain open to support the research of investigational tests, vaccines, and medications intended for commercial release.

Meridian sites are working with Sponsors and contract research organizations (CROs) to ensure patient safety while continuing to enroll patients during the COVID-19 pandemic. The company has enrolled more than 25,000 subjects into vaccine and infectious disease clinical trials in the past 20 years. Nicole Osborn, CEO, says Meridian has always focused on protecting healthy participants and patients with acute conditions.

“We’re fully prepared to address any COVID-19 opportunity and support novel research and development programs,” said Osborn. “Our clients can expect Meridian to be fully staffed and operational throughout this pandemic. Our patients can be confident that every Meridian site is meeting and exceeding safety standards, and that we’re operating in line with state-specific regulations.”

To maintain proper social distancing, Meridian is supporting over-the-phone visits, telemedicine visits, and in-office visits with minimal exposure to others and intensified cleaning processes. In early March, Meridian began restricting work-related travel and in-person meeting attendance.

As a leading investigative site network for vaccine trials, Meridian has conducted first-in-human studies for emerging diseases. In 2015, the company supported a Phase I study for the Ebola vaccine when the outbreak occurred, and conducted research for Zika virus and anthrax vaccines in the past year.

Headquartered at its dedicated research center in Omaha, Nebraska, the company operates additional sites in Nebraska (Norfolk), Georgia (Savannah), Louisiana (Baton Rouge), Maryland (Rockville), New York (Binghamton, Endwell, Johnson City, Vestal), South Dakota (Dakota Dunes), and Virginia (Norfolk).

Sponsors and CROs interested in leveraging Meridian’s network for infectious disease trials should contact Andrew Kimball, vice president, business development at akimball@mcrmed.com.

“We’re here to educate patients and people interested in the research process,” said Osborn. “The spread of COVID-19 gives us a chance to engage and inform more people about the importance of clinical research to address viruses like SARS-CoV-2.”

Patients who are currently enrolled in a Meridian trial are encouraged to call the site they’re visiting or the Meridian call center: (402) 934-7563 (LA, NE, SD) • (912) 623-2240 (GA, MD, NY, VA).

Visit mcrmed.com/vaccine to learn more about Meridian’s infectious disease capabilities. To view current studies and sign up to learn about new opportunities at Meridian’s locations across the U.S., visit mcrmed.com.

Read the full press release on prweb.com: http://www.prweb.com/releases/meridian_clinical_research_continues_to_support_trials_at_sites_nationwide_will_remain_operational_amid_covid_19_pandemic/prweb16999427.htm